Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HORIZON: Tezepelumab in 5 to < 12 Year Old Children With Severe Uncontrolled Asthma
jRCT2071230072Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Tezepelumab with Placebo (2 arms). Primary endpoint: Annualized asthma exacerbation rate (AAER). Started Jan 2024; status: recruiting.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on jRCT2071230072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230072.